Ownership and insider activity for Viking Therapeutics, Inc. (VKTX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß).
Price
| Price | $26.09 (closing price, November 3, 2026) |
| Market Cap | $3.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | A-Award | 40,800 | $1.3M |
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | A-Award | 6,333 | |
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | |||
| 2026-07-28 | Lian Brian | A-Award | 221,667 | |
| 2026-07-29 | Lian Brian | S-Sale | 148,517 | $4.9M |
| 2026-07-28 | ZANTE GREG | A-Award | 31,667 | |
| 2026-07-29 | ZANTE GREG | S-Sale | 21,217 | $710K |
| 2026-07-28 | Mancini Marianna | A-Award | 31,667 | |
| 2026-07-29 | Mancini Marianna | S-Sale | 18,217 | $610K |
| 2026-06-01 | Chen Hubert C | A-Award | 190,000 | $5.9M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $9.0M | $24.8M | $8.4M | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M |
| Short-term Investments | $10.1M | $11.6M | $276.7M | $267.3M | $219.3M | $175.7M | $118.9M | $306.6M | $875.9M | $539.9M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $14.0M | $21.9M | $302.1M | $283.5M | $256.1M | $210.5M | $167.0M | $367.2M | $907.2M | $715.6M |
| Property, Plant & Equipment | 0 | 0 | 0 | $598,000 | $321,000 | $25,000 | $1.4M | $1.1M | $1.0M | $85,000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $14.5M | $22.1M | $302.3M | $284.3M | $256.5M | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M |
| Accounts Payable | $1.2M | $1.5M | $959,000 | $2.4M | $4.0M | $1.4M | $8.5M | $7.5M | $9.8M | $53.3M |
| Short-term Debt | $3.3M | $3.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.5M | $8.7M | $4.5M | $6.8M | $12.1M | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.5M | $8.7M | $4.6M | $7.1M | $12.2M | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M |
| Retained Earnings | -$60.3M | -$80.9M | -$102.9M | -$128.7M | -$168.2M | -$223.2M | -$292.0M | -$377.9M | -$487.9M | -$847.5M |
| Total Equity | $8.0M | $13.5M | $297.8M | $277.1M | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M |
| Total Debt | $3.3M | $3.5M | 0 | $662,000 | $359,000 | $29,000 | $1.6M | $1.3M | $1.1M | $137,000 |
| Net Debt | -$9.9M | -$17.1M | -$301.5M | -$275.0M | -$248.0M | -$202.1M | -$153.9M | -$360.8M | -$901.5M | -$705.6M |
| Working Capital | $7.5M | $13.2M | $297.6M | $276.7M | $244.0M | $201.8M | $145.1M | $348.1M | $879.8M | $638.9M |
Financial Health
| Debt / Equity | 0.43 |
| Current Ratio | 7.27 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 28.62 |
Profitability
| Return on Equity | -117.35% |
| Return on Invested Capital | -76.91% |
| Return on Assets | -64.19% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: MDGL · NAMS · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of VKTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks